Saturday, November 14, 2026

USD/EUR Bearish Momentum: 0.94% Down In The Last 10 Sessions

ViaNews Editorial Team

October 11, 2023

Automated market report from our archive (2020–2024), published before source-traceability. How we work

USD/EUR Bearish Momentum: 0.94% Down In The Last 10 Sessions

(VIANEWS) - USD/EUR (USDEUR) has been up by 0.94% for the last 10 sessions. At 08:07 EST on Wednesday, 11 October, USD/EUR (USDEUR) is $0.94.

USD/EUR's yearly highs and lows, it's 6.314% up from its 52-week low and 9.144% down from its 52-week high.

Volatility

USD/EUR's last week, last month's, and last quarter's current intraday variation average was a negative 0.25%, a positive 0.03%, and a positive 0.31%, respectively.

USD/EUR's highest amplitude of average volatility was 0.25% (last week), 0.29% (last month), and 0.31% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, USD/EUR's Forex is considered to be overbought (>=80).

News about

  • Usd/jpy treading water near 148.60 as investors sniff out US inflation figures. According to FXStreet on Wednesday, 11 October, "The USD/JPY continues to soar high above the 200-day Simple Moving Average (SDMA), which is currently riding up into the 139.00 chart region, with technical support for the pair currently sitting near 147.00 from the 50-day SMA.", "The long-term trend outlook for the USD/JPY is exceedingly bullish, with the Greenback trading well above the median against the Yen. "
  • Usd/jpy technical analysis: demand for buying safe havens - 10 October 2023. According to DailyForex on Tuesday, 10 October, "Accordingly, the USD/JPY currency pair jumped towards the resistance level of 149.23 before settling around the level of 148.70 at the time of writing the analysis. ", "Therefore, USD/JPY is likely to continue rising as buyers target the next major resistance level at 151.96 (October 22 high). "
  • Usd/jpy drops on risk-aversion spurred on middle-east tensions, falling US bond yields. According to FXStreet on Monday, 9 October, "The USD/JPY remains neutral to upward bias, with price action remaining above the Ichimoku Cloud (Kumo). ", "On the other hand and the path of least resistance, the USD/JPY could test the 150.00 figure, but first it needs to conquer 149.00"
  • Usd/jpy price analysis: struggles to capitalize on modest intraday bounce from one-week low. According to FXStreet on Tuesday, 10 October, "A generally positive risk tone is seen undermining the safe-haven Japanese Yen (JPY) and turning out to be a key factor lending some support to the USD/JPY pair. ", "From a technical perspective, the USD/JPY pair now seems to have found acceptance below the 100-period Simple Moving Average (SMA) on the 4-hour chart. "
  • Usd/jpy oscillates at around 148.60 amidst dovish fed remarks, risk-on impulse. According to FXStreet on Tuesday, 10 October, "Nevertheless, the USD/JPY rally was capped by the US Treasury bond yields plunge as the 10-year benchmark note sits at 4.632%, dropping 17 basis points since Monday."

More news about USD/EUR (USDEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,577 source documents archived
Query this data → isubstrate.com